(Q33671198)

28 July 2017

title

Trends in the treatment of localized prostate cancer using supplemented cancer registry data (English)

1 reference

28 July 2017

1 reference

Richard Hoffman

4

0 references

David F. Penson

object named as

David F Penson

7

0 references

Dennis Deapen

6

object named as

Dennis Deapen

1 reference

28 July 2017

1

Ann S Hamilton

1 reference

28 July 2017

Peter C Albertsen

2

1 reference

28 July 2017

Terri Kang Johnson

3

1 reference

28 July 2017

Donna Morrell

5

1 reference

28 July 2017

publication date

24 August 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

107

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

576-584

1 reference

National Comprehensive Cancer Network guidelines for the management of prostate cancer

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Quality of life after treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Nonmedical factors in treatment selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

The patient's dilemma: prostate cancer treatment choices

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Treatments for prostate cancer in older men: 1984-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Comparison of self-reported initial treatment with medical records: results from the prostate cancer outcomes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Geographic variation across veterans affairs medical centers in the treatment of early stage prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Racial/ethnic disparities in the treatment of localized/regional prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Geographic and socioeconomic variation in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Treatment decision-making strategies and influences in patients with localized prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Erectile function after prostate brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09514.X

10.1111/J.1464-410X.2010.09514.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference